KOSDAQElectronic Components119610

Interojo

₩12,650▼ 0.32%2026-11-18 close
Market Cap
₩144.4B
Turnover
₩200M
Volume
20K
Shares out.
11.4M
PER
9.8×
PBR
1.0×
EPS
₩1,361
Dividend Yield
4.88%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩650 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Rebound Meets a Cost-Ratio Test in Q3 2026

Interojo's operating margin recovered to 16.4% in 2025, but quarterly operating profit has fallen since its fourth-quarter 2025 peak, making cost ratios and production yield the next items to watch.

  1. 1

    Annual operating profit recovered from KRW 5.82 billion in 2024 to KRW 19.5 billion in 2025, a 235.0% increase.

  2. 2

    Q3 2026 sales of KRW 36.2 billion were reported as a quarterly record, based on company IR materials cited by Lead Economy.

  3. 3

    The cost of sales ratio rose 13.7 percentage points quarter on quarter to 67.5%, and operating profit has now declined for three straight quarters.

  4. 4

    Overseas sales made up 80% of Q3 2026 revenue, and Japan sales rose 95% quarter on quarter to KRW 16.4 billion.

  5. 5

    Japan PMDA approval is targeted for the first half of 2027, and attributable net income for the last four quarters totals KRW 17 billion.

02

Business structure

Interojo, founded in 2000, manufactures and sells contact lenses and, according to a Money Today report, supplies products to more than 60 countries through ODM and OEM arrangements. The company combines manufacturing with its own brands, and its flagship brand Clalen produces silicone hydrogel color lenses in-house.

In February 2026, Clalen won the color and beauty contact lens category of Forbes Korea's '2026 Best Brand Award' for consumers.

According to a Kiwoom Securities report, the company runs Plant A with 7 lines for one-day and FRP clear lenses, Plant C with 38 lines for one-day color lenses, and Plant S with 11 lines for silicone clear and color lenses.

Its product lineup covers one-day lenses, frequent-replacement (FRP) lenses, and silicone clear and color lenses. In Q1 2026, overseas sales were KRW 24.0 billion, or 78% of the total, with clear lenses at KRW 11.7 billion and FRP lenses at KRW 11.1 billion.

In Q3 2026, overseas sales reached KRW 29.1 billion, or 80% of revenue, and Japan accounted for KRW 16.4 billion, or 45%. Exports reach Japan, Russia, Kuwait, China, Saudi Arabia, France, and the Czech Republic, according to customs data reported by a local outlet.

Competitively, Interojo emphasizes its combination of manufacturing capability and brands, and silicone hydrogel color lenses are classed as a high-barrier segment because they demand strict process stability.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩32.4B₩4.7B14.6%
2025Q4₩31.6B₩6.2B19.7%
2026Q1₩30.7B₩6.2B20.3%
2026Q2₩29.4B₩6B20.3%
2026Q3₩36.2B₩5.8B16.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩117.8B₩24.2B₩18.6B20.5%10.4%44.6%
2023₩121.8B₩18.3B₩13.8B15.0%7.3%48.5%
2024₩115.8B₩5.8B₩200M5.0%0.1%37.9%
2025₩118.4B₩19.5B₩12.9B16.4%8.2%56.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales moved from KRW 117.8 billion in 2022 to KRW 121.8 billion in 2023 (up 3.4% year on year), fell to KRW 115.8 billion in 2024 (down 4.9%), and recovered to KRW 118.4 billion in 2025 (up 2.2%). Among 2022 to 2025, 2023 was the largest year and 2024 the smallest.

Operating profit went from KRW 24.2 billion in 2022 to KRW 18.3 billion in 2023 (down 24.2%) and KRW 5.82 billion in 2024 (down 68.2%), then rose to KRW 19.5 billion in 2025 (up 235.0%).

Operating margin was 20.5% in 2022, 15.0% in 2023, 5.0% in 2024, and 16.4% in 2025, so the margin was lowest in 2024, the year of smallest sales. Media and the company attributed the 2025 profit recovery to better cost structure and a higher mix of high-value products.

Attributable net income was KRW 18.6 billion in 2022, KRW 13.8 billion in 2023 (down 26.0%), KRW 184 million in 2024 (down 98.7%), and KRW 12.9 billion in 2025 (up 6,918.7%).

Quarterly operating profit peaked at KRW 6.24 billion in Q4 2025 (up 32.3% quarter on quarter) and then declined for three consecutive quarters to KRW 6.23 billion in Q1 2026, KRW 5.98 billion in Q2, and KRW 5.81 billion in Q3.

The company said Q2 2026 sales of KRW 29.4 billion reflected some product shipments shifting into Q3, and Q3 sales rose to KRW 36.2 billion (up 23.0% quarter on quarter). However, Lead Economy, citing company IR materials, reported that the Q3 cost of sales ratio rose 13.7 percentage points to 67.5%.

Production volume fell 29% during a new-product transition, from 94 million to 67 million units, and currency effects added pressure; excluding currency effects, the cost ratio was 65.4%.

Attributable net income peaked at KRW 4.96 billion in Q1 2026 and then fell for two straight quarters to KRW 4.78 billion in Q2 and KRW 3.04 billion in Q3, and the last four quarters total KRW 17 billion.

At end-2025, total equity was KRW 157 billion and total liabilities KRW 87.9 billion, with the debt ratio rising from 37.9% in 2024 to 56.0% in 2025. Operating cash flow went from KRW 12 billion in 2022 to KRW 25.3 billion in 2025.

05

Industry analysis

In contact lenses, silicone hydrogel color lenses demand both high oxygen permeability and process stability, which places them among the higher-barrier segments.

Private equity investment has continued across lens makers, and analysts note that the market's attention has gathered on companies that combine manufacturing capability with their own brands.

Kiwoom Securities highlights Interojo's internalization of both production facilities and its proprietary brands, and cites this as a basis for possible re-rating. The company's overall yield rose from 62% in 2024 to 75% in 2025, and Kiwoom Securities estimated it could reach 85% in 2026.

Kiwoom's report also says a new axis-fixed lens product is supplied to more than 200 Don Quijote stores in Japan, with new orders continuing.

On regulation, FDA 510(k) clearance is a substantial-equivalence pathway, and Interojo announced in January 2026 that a US trial of 75 subjects over three months at three sites showed results equivalent to the control lens.

A Japan PMDA application began in the same period, so US and Japanese approvals are running in parallel. On brands, the company has added an advertising model and is rebranding Clalen, and Daishin Securities expected advertising spending to offset some of the profit benefit of higher sales. Clalen received an external brand award in February 2026, which points to consumer recognition.

06

Outlook

For Q4 2026, the company said it is pursuing a rise in re-orders of axis-fixed lenses for Japan, a domestic new-product launch, and clearer prospects for additional FDA approvals.

Its 2027 targets include restoring profitability through better production yields, broadening its overseas customer portfolio, and securing Japan PMDA approval. The key to margin recovery is how quickly the production decline during the new-product transition, which drove the Q3 cost ratio higher, reverses.

Kiwoom Securities estimated 2026 overall yield could climb to 85%, but that is a brokerage estimate rather than a company-disclosed figure. Axis-fixed lens volume whose revenue recognition slipped from Q2 was reported as reflected in Q3, and the company expected deferred sales to rebuild growth after Q3.

Daishin Securities had noted that higher advertising spending would not translate directly into better profitability. A US FDA 510(k) clearance for a silicone hydrogel product was reported in late May 2026, and further approvals will shape the pace of US expansion.

The Japan PMDA approval is targeted for the first half of 2027, and the outcome will determine how Japan sales can expand further.

07

Valuation

PER
9.8×
PBR
1.0×
ROE
10.8%
EPS
₩1,361
BPS
₩13,585
Dividend per share
₩650

Current multiples move with the share price every day, so this section only describes their level in relative terms. The price-to-book ratio sits close to net asset value, which means the premium over book equity is not large.

The dividend yield also changes with the share price, so it is best read as the amount returned relative to the price. For the price-to-earnings ratio, the last four quarters' attributable net income of KRW 17 billion and 2025 attributable net income of KRW 12.9 billion show how earnings scale feeds into the multiple.

In a year like 2024, when earnings fell sharply, the earnings-based multiple rose even at a similar share price, so past multiple ranges are hard to compare directly. The key question for valuation is how far the multiple has priced in the earnings recovery from a 5.0% operating margin in 2024 to 16.4% in 2025.

Simple multiple comparisons with listed peers leave wide room for interpretation, because Interojo combines manufacturing with its own brands.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Profitability recovery

Operating margin climbed from 5.0% in 2024 to 16.4% in 2025 and held at 16.0% in Q3 2026, according to company IR data reported by Lead Economy. The company and media attribute the recovery to cost-structure improvements and a higher mix of high-value products.

Silicone hydrogel color lenses, which demand high process stability, are cited as a basis for product differentiation.

Overseas and Japan sales expansion

Q3 2026 overseas sales rose 24% quarter on quarter to KRW 29.1 billion, and Japan sales jumped 95% to KRW 16.4 billion, or 45% of the total, according to Lead Economy. Kiwoom Securities reported that new products have been delivered to more than 200 Don Quijote stores in Japan and that new orders are continuing.

The same report notes that axis-fixed lenses carry higher technical difficulty and therefore higher unit prices.

US and Japan regulatory progress

In January 2026 the company announced that its test lens showed safety and efficacy equivalent to the control lens in a US clinical trial. FDA 510(k) clearance was reported in late May 2026. The Japan PMDA application began in January 2026, with approval targeted for the first half of 2027.

09

Bear factors

Higher Q3 cost ratio

The Q3 2026 cost of sales ratio rose 13.7 percentage points quarter on quarter to 67.5%. Production fell 29% during the new-product transition and currency effects added pressure, while the ratio excluding currency effects was 65.4%, per Lead Economy.

If the cost ratio does not come down, higher sales may not translate into a proportional rise in operating profit.

Three straight quarters of lower operating profit

Operating profit peaked at KRW 6.24 billion in Q4 2025 and then declined to KRW 6.23 billion in Q1 2026, KRW 5.98 billion in Q2, and KRW 5.81 billion in Q3. Q3 sales rose to KRW 36.2 billion, but profit did not keep pace.

Daishin Securities, in its Q3 preview, noted that higher advertising spending could offset the profit benefit of higher sales.

Revenue timing and balance sheet

Q2 2026 sales of KRW 29.4 billion reflected some product shipments being recognized in Q3, according to the company. The debt ratio rose from 37.9% at end-2024 to 56.0% at end-2025. Quarterly swings driven by revenue recognition timing are also a weakness.

10

Risk factors

Currency and cost ratio

With overseas sales at 80% of revenue, currency moves directly affect translated sales and the cost ratio. The company cited currency as a factor in the Q3 cost increase, and the ratio excluding currency effects was 65.4%. A shift in exchange rates could widen quarter-to-quarter swings in operating margin.

Regulatory timing

Additional FDA approvals are at the stage the company describes as pursuing clearer prospects in Q4, and Japan PMDA approval is targeted for the first half of 2027. If approvals slip, the timing of overseas customer expansion and product line extensions could also shift.

Balance sheet and concentration

The debt ratio rose to 56.0% at end-2025 from 37.9% at end-2024, with total liabilities of KRW 87.9 billion. Japan accounted for 45% of Q3 2026 sales, which concentrates dependence on one country's demand and delivery schedules. When earnings swing, these two factors could reduce the cushion available to absorb them.

11

What to watch next

  1. Q4 2026

    Watch re-orders of axis-fixed lenses for Japan, the domestic new-product launch, and progress on additional US FDA approvals. How far the 67.5% Q3 cost of sales ratio declines is the first indicator for operating profit trends.

  2. By late March 2027

    The 2026 annual report is due. It will show the full-year operating margin, full-year attributable net income, and whether the debt ratio, at 56.0% at end-2025, has changed.

  3. Around May 2027

    The Q1 2027 earnings release. It will show whether operating profit has broken its three-quarter decline and whether yield gains are reflected in the cost ratio.

  4. First half of 2027

    Whether Japan PMDA approval is granted. Whether the target date is met marks the checkpoint for the Japan sales expansion path.

12

Overall view

Interojo's operating margin recovered from 5.0% in 2024 to 16.4% in 2025 and held at 16.0% in Q3 2026, so the scale of the profitability recovery is clear. However, the cost of sales ratio rose to 67.5% in the same quarter, and operating profit has declined for three straight quarters since its Q4 2025 peak.

Strengths include high-value silicone hydrogel products, expanding overseas and Japan sales, and preparation for US FDA and Japan PMDA approvals. Weaknesses include production declines during the new-product transition, cost pressure, higher advertising spending, and a debt ratio that rose to 56.0% at end-2025.

Which side outweighs the other is hard to judge from disclosed figures alone and will be confirmed in upcoming disclosures. The next checkpoints are the Q4 2026 cost ratio, the full-year operating margin in the 2026 annual report, Q1 2027 operating profit, and the timing of Japan PMDA approval.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. opticallife.co.kr
  2. junggi.co.kr
  3. mt.co.kr
  4. m.news.nate.com
  5. mt.co.kr
  6. m.news.nate.com
  7. m.news.nate.com
  8. newspim.com
  9. openbizdata.com
  10. vegannews.co.kr
  11. vegannews.co.kr
  12. comp.fnguide.com
  13. pinpointnews.co.kr
  14. kr.investing.com
  15. leadeconomy.co.kr
  16. infostockdaily.co.kr
  17. manilatimes.net
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis